Lantheus Holdings, Inc. $LNTH Shares Sold by Crescent Grove Advisors LLC

Crescent Grove Advisors LLC lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 53.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 6,907 shares of the medical equipment provider’s stock after selling 8,000 shares during the period. Crescent Grove Advisors LLC’s holdings in Lantheus were worth $687,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the company. Jupiter Topco LLC bought a new stake in shares of Lantheus during the 2nd quarter valued at $575,628,000. Reinhart Partners LLC. raised its position in Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock valued at $177,437,000 after purchasing an additional 34,501 shares in the last quarter. Carmignac Gestion lifted its position in shares of Lantheus by 0.9% during the 2nd quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock worth $148,671,000 after buying an additional 12,100 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Lantheus by 440.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after buying an additional 582,661 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its stake in shares of Lantheus by 59.4% in the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock valued at $49,284,000 after purchasing an additional 242,222 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

LNTH has been the subject of a number of research reports. Citizens Jmp reiterated a “market outperform” rating and issued a $115.00 price objective on shares of Lantheus in a report on Monday, June 29th. Weiss Ratings cut Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, October 15th. Leerink Partners set a $102.50 target price on Lantheus in a research note on Monday, August 3rd. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Finally, Truist Financial lowered shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the company from $125.00 to $102.50 in a research report on Monday, August 3rd. Three equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $107.44.

Lantheus Price Performance

LNTH stock opened at $100.10 on Friday. The firm has a 50 day simple moving average of $100.32 and a two-hundred day simple moving average of $98.58. The stock has a market cap of $6.54 billion, a PE ratio of 20.13 and a beta of -0.06. Lantheus Holdings, Inc. has a one year low of $50.15 and a one year high of $111.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. During the same period last year, the business earned $1.57 earnings per share. The business’s quarterly revenue was up 2.7% on a year-over-year basis. On average, analysts predict that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.